Recent news and filings highlight Amarin's Q2 2026 earnings call and financial results, ongoing patent litigation developments, and operational updates including restructuring and collaboration risks.

• Amarin held its Q2 2026 earnings call with transcripts and highlights published, reporting earnings that exceeded some expectations but with revenues falling short [N2][N4][N5].
• The company reported a net loss of $7.65 million for Q2 2026 and EPS of -$0.02, with cash and short-term investments totaling over $314 million as of June 30, 2026 [S2].
• Ongoing patent litigation against Hikma is currently stayed pending U.S. Supreme Court review, with the company continuing to vigorously enforce its intellectual property rights [S1].
• Amarin's collaboration partner Recordati faces risks related to marketing authorizations and commercialization efforts in Europe, which could impact payments and profitability [S1].
• The company has recently reduced its sales force in the U.S. and Europe as part of a restructuring plan, which may affect future revenues and expenses [S1].

Amarin benefits from a proprietary drug, VASCEPA/VAZKEPA, approved for cardiovascular risk reduction with established market presence in the U.S. and Europe. The company maintains a robust patent portfolio and is actively defending its intellectual property, which could sustain its competitive position. Strategic collaborations, such as with Recordati in Europe, provide expanded commercialization capabilities. The company holds strong liquidity with substantial cash and investments, supporting ongoing operations and development. Recent earnings calls and news indicate active management of commercialization and operational execution.

Amarin has a history of operating losses and has not achieved sustained profitability, with significant accumulated deficits. The company faces ongoing patent litigation with uncertain outcomes that could impact its business. Dependence on a limited number of customers and collaboration partners introduces concentration risks. The pharmaceutical market is competitive, with potential generic entrants and alternative therapies challenging VASCEPA's market share. Cybersecurity risks and potential disruptions to operations pose additional challenges. The company’s financial results continue to show net losses, and its ability to generate consistent revenue and profits remains uncertain.

Amarin's competitive moat is primarily based on its intellectual property portfolio protecting VASCEPA/VAZKEPA, including issued patents and pending applications, as well as trade secrets and know-how. The company actively enforces its patents through litigation to defend against generic competition, although such processes are costly and outcomes uncertain. Its collaboration with Recordati for European commercialization extends its market reach. However, the pharmaceutical industry is highly competitive with larger players potentially challenging patents and developing alternative therapies. The company's moat is thus dependent on the strength and enforceability of its patents, successful commercialization partnerships, and continued market acceptance of VASCEPA.

• Patent Litigation and Intellectual Property Risks: Amarin is engaged in ongoing patent litigation, including a key lawsuit against Hikma regarding generic icosapent ethyl capsules. The outcome is uncertain and could materially affect the company's business. Patent enforcement is costly and time-consuming, with no guarantee of success or prevention of generic competition.
• Profitability and Operating Losses: The company has a history of net losses and an accumulated deficit. Continued operating losses are anticipated due to significant commercialization and R&D expenses, with no assurance of achieving sustained profitability.
• Customer Concentration: A significant portion of sales is concentrated among three customers, posing risks if business with any major customer decreases or is lost.
• Dependence on Collaboration Partners: Amarin relies on Recordati for commercialization of VAZKEPA in Europe. Risks include marketing authorization delays, partner's commercialization efforts, supply chain management, pricing, and strategic focus.
• Cybersecurity Risks: The company faces risks from potential breaches of internal and third-party information systems, which could disrupt operations, cause data loss, and damage reputation.

• Amarin Corporation plc is a pharmaceutical company focused on the commercialization of VASCEPA/VAZKEPA (icosapent ethyl), a drug approved by the U.S. FDA for marketing in the U.S. for two important indications and authorized in Europe and other smaller jurisdictions [S1].
• The company has been generating product revenue from sales of VASCEPA since January 2013 but has not yet reached sustained profitability, reporting net losses of approximately $38.8 million, $82.2 million, and $59.1 million for fiscal years 2025, 2024, and 2023 respectively, with an accumulated deficit of $1.7 billion as of December 31, 2025 [S1].
• Amarin's ability to become profitable depends on market acceptance and commercial success of VASCEPA, manufacturing capabilities through third parties, and effective marketing and sales efforts including strategic collaborations [S1].
• The company has a history of operating losses and anticipates continued losses for an indefinite period due to significant expenses related to commercialization and research and development [S1].
• Amarin has a patent portfolio protecting VASCEPA and its use, including pending patent applications in the U.S. and internationally, but patent litigation is ongoing and costly, with no assurance of successful enforcement or prevention of generic competition [S1].
• A patent infringement lawsuit against Hikma regarding generic icosapent ethyl capsules is currently stayed pending appeal before the U.S. Supreme Court, with uncertain outcome and potential business impact [S1].
• The company relies on trade secrets and know-how in addition to patents to protect its competitive position but acknowledges the difficulty in fully protecting trade secrets [S1].
• Amarin faces risks related to customer concentration, with three customers accounting for significant portions of U.S. gross product sales and accounts receivable as of December 31, 2025 [S1].
• The company has a collaboration partner, Recordati, for commercialization of VAZKEPA in 59 European countries, with risks related to marketing authorizations, commercialization efforts, supply chain management, pricing, and strategic focus of the partner [S1].
• Amarin has recently reduced its sales force in the U.S. and Europe as part of a Global Restructuring Plan, which may affect revenues and expenses [S1].
• The company is subject to cybersecurity risks including potential breaches of internal and third-party systems, which could disrupt operations and result in liabilities or reputational damage [S1].
• As of June 30, 2026, Amarin reported cash and cash equivalents of $143.6 million, short-term investments of $171.1 million, current assets of $602.8 million, and current liabilities of $164.2 million, resulting in a current ratio of 3.67 and a cash ratio of 1.92 [S2].
• For the quarter ended June 30, 2026, Amarin reported a net loss of $7.65 million and basic and diluted EPS of -$0.02 [S2].
• Recent news includes Amarin's Q2 2026 earnings call and related reports indicating earnings beat estimates but revenues fell short, with detailed call highlights available [N2][N4][N5].